TickerTalks
Browse all tickers →
TickerTalks›$IBRX
IBIBRX

ImmunityBio, Inc.

$IBRX·$8.0B·Biotechnology·Healthcare
$7.95-1.2%YTD+244.1%1Y+234.0%
Mentions · last 7 days
2026-08-21: 54 posts2026-08-22: 28 posts2026-08-23: 35 posts486+1%
Price updated 2h ago·X counts updated 8d ago
IBIBRX
$IBRXImmunityBio, Inc.
$7.95-1.24%486 posts+1%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $IBRX, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Driven by hypeCooling offAI verdict · as of 2026-08-31

Catching its breath after a run — could pick back up or fade from here.

The bladder-cancer immunotherapy ramp that spawned a 245% year — ANKTIVA scaling, Cambridge Equities at 24.7%, and 128M shares short at 33% borrow.

ImmunityBio is a clinical-stage oncology company whose lead product ANKTIVA (nogapendekin alfa) is a first-in-class IL-15 superagonist for bladder cancer. The equity has more than tripled over the last twelve months as ANKTIVA's commercial ramp beat expectations and label-expansion catalysts came into view.

  • The commercial arc is genuinely there: Q2 net product revenue of $50.7M grew 92% year-over-year — the eighth consecutive sequential-growth quarter — and consensus now models $222M FY26 revenue expanding to $1.09B by FY28 as the label widens.
  • The regulatory optionality is meaningful: the Jan 6, 2027 PDUFA for label expansion (moving ANKTIVA beyond current indications) plus a new sepsis trial and international reach into 34 countries after UAE and Saudi approvals give the FY27 estimate ($436M revenue) real underwriting foundation.
  • The short-interest setup is the near-term fuel: 128M shares short at a 33% borrow rate against a ~$8B market cap makes any positive catalyst a squeeze — every commercial milestone or PDUFA-related headline sends the borrow tighter and forces covering.
  • Insider tape is quiet and Cambridge Equities' 13D/A holds 24.7% — a large-holder anchor without visible selling is what has kept the equity from breaking despite the class-action investigation (Kessler Topaz Meltzer & Check, Aug 21) landing at the same time.

The path if it works is a Nov 3 Q3 print with ANKTIVA revenue crossing $60M plus positive commentary on the Jan 2027 PDUFA — the squeeze pressure keeps building and the tape extends higher. What confirms the cooling is a Q3 that shows sequential growth decelerating for the first time in a year; that's when 128M shorts stop being fuel and start looking like an accurate read on a de-rating.

Agrees with X sentimentThe bullish X frame — ANKTIVA Q2 net product revenue up 92% YoY, eighth consecutive sequential growth quarter, regulatory reach into 34 countries after UAE and Saudi approvals, the Jan 6, 2027 PDUFA for label expansion, and 128M shares short at a 33% borrow rate framed as squeeze fuel — captures the setup correctly; the honest frustration with FDA delays and short-driven price action is the counterweight that keeps this a cooling trajectory rather than a clean acceleration.

What to watch: The Nov 3 Q3 print — ANKTIVA revenue crossing $60M plus positive Jan 2027 PDUFA commentary keeps the squeeze pressure building; a sequential-growth decelerating for the first time in a year is what confirms the cooling into a de-rating.

On the calendar: 2026-11-03 — Q3 2026 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment96 posts analyzed · as of 2026-08-30

Conviction is fervent among ImmunityBio longs, framing ANKTIVA's commercial arc as the story: Q2 net product revenue of $50.7M up 92% YoY, an eighth straight sequential-growth quarter, and regulatory reach into 34 countries after UAE and Saudi approvals. Bulls point to a Jan 6, 2027 PDUFA for label expansion, a new sepsis trial, and 128M shares short with a 33% borrow rate as squeeze fuel. Frustration with FDA delays and short-driven price action colors the tone.

Read the AI verdict + X sentiment for $IBRX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops immunotherapy and cell therapy platforms targeting bladder, pancreatic, and lung cancers, plus infectious disease vaccines.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $IBRX.

Biotechnology · Healthcare

GLP-1 oral formulation competition — emerging clinical data from pipeline challengers — is the central bifurcation: platform holders (LLY, NVO) defend on efficacy breadth while precision oncology names decouple entirely. FDA catalyst cadence over the next 60 days sets the near-term tone.

What this means for $IBRX

Neutral — binary clinical-stage catalyst set is independent of the broader industry macro driver; pipeline readout timing is the company-specific event.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+48.9%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-8.3How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-44.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-185%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-4.1%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
51.4Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
139%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
93.8%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
-1.3Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 4, 2026$-0.22$-0.08-175.0%
Q1 2026May 7, 2026$-0.62$-0.08-675.0%
Q4 2025Feb 23, 2026$-0.06$-0.08+25.0%
Q3 2025Nov 4, 2025$-0.07$-0.10+30.0%
Next earningsTue, Nov 3·consensus EPS $-0.08

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$44.2M+167.6%99.5%-158%$-0.62$-77.1M
Q4 FY25$38.3M+407.0%88.9%-169%$-0.06$-71.2M
Q3 FY25$32.1M+425.1%87.1%-174%$-0.07$-69.7M
Q2 FY25$26.4M+2423.9%99.5%-270%$-0.10$-80.8M

Forward consensus

5-year forecast · up to 3 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$222.4M$195.9M – $248.9M-$0.83-$0.86 – -$0.803
FY27$436.5M$237.7M – $635.2M-$0.15-$0.36 – $0.063
FY28$1.1B$766.2M – $1.4B$0.36$0.19 – $0.532
FY29$1.8B$1.3B – $2.5B$0.88$0.54 – $1.341
FY30$2.5B$1.8B – $3.6B$1.41$0.86 – $2.151

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.9×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.58%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+2.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+24.8%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 113.8M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today7.0% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.135-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJul 2Cheryl CohenDirector131.2K sh$1.2MSellJul 1Christobel SeleckyDirector159.5K sh$1.4MSellJun 30Christobel SeleckyDirector1.0K sh$9KSellJun 29Christobel SeleckyDirector95.7K sh$862KSellJun 24Barry J. SimonDirector25.0K sh$197KSellJun 4Barry J. SimonDirector23.0K sh$165K
+ 11 other (6 awards · 4 exempts · 1 conversion) in window

See when $IBRX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

SC 13D/AActivist amendmentAug 6SC 13D/A
AI summary

Cambridge Equities, LP 2 Check the appropriate box if a membe amended its 13D filing disclosing a beneficial ownership position of 24.7% in IBRX (IBRX) as of 2026-08-06. The filer indicated plans: purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that sec. This is a material ownership disclosure indicating significant shareholder interest that may signal activist or strategic intent. Investors should monitor for further 13D amendments, which could indicate evolving positions or demands on management.

8-KPress release / Reg FDJul 308-K — Item 7.01: Press release / Reg FD
AI summary

IBRX (IBRX) filed an 8-K under Reg FD (Item 7.01) on 2026-07-30, posting a press release to its website or furnishing it to the SEC. On July 29, 2026, ImmunityBio, Inc. (“ImmunityBio” or the “Company”) issued a press release announcing that the Emirates Drug Establishment (“EDE”) of the United Arab Emirates (“UAE”) has granted marketing authorization for ANKTIVA ® across two indic This is an informational disclosure furnished (not filed) and does not create new liability under the Exchange Act. Materiality depends on the content of the presentation.

8-KShareholder voteJun 108-K — Item 5.07: Shareholder vote
AI summary

ImmunityBio, Inc. held its 2026 Annual Meeting on June 9, 2026, with approximately 85% of outstanding shares represented. Stockholders re-elected all nine incumbent directors (including founder/CEO Patrick Soon-Shiong) and ratified Deloitte & Touche LLP as auditor for fiscal 2026. Routine governance for a founder-controlled company; high participation rate reflects institutional engagement.

8-KMaterial agreementMay 188-K — Item 1.01: Material agreement · Item 7.01: Press release / Reg FD
AI summary

ImmunityBio, Inc. (IBRX) entered into an exclusive development and supply agreement with Japan BCG Laboratory (JBL) on May 14, 2026 for JBL to exclusively manufacture and supply the Tokyo-172 BCG strain for ImmunityBio's use in the U.S. and territories. ImmunityBio bears all development, clinical, and regulatory responsibilities for a 10-year initial term from FDA approval; no payments to JBL are due until approval, with at least 2 batches per year required post-approval. This agreement secures ImmunityBio's critical BCG supply chain ahead of anticipated commercial launch — a potentially material commercial enabler contingent on FDA approval.

8-KPress release / Reg FDApr 68-K — Item 7.01: Press release / Reg FD
AI summary

IBRX filed an 8-K Item 7.01 (Reg FD) disclosure dated 2026-04-06. Reg FD disclosures make material information simultaneously available to all investors; content may include guidance updates, strategic plans, or preliminary results.

8-KMaterial agreementMar 318-K — Item 1.01: Material agreement · Item 2.03: Material debt obligation · Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

IBRX entered into a amendment (8-K Item 1.01, dated 2026-03-31). Size: approximately $75.0 million. Material definitive agreement — investors should review the full exhibit for covenants, conditions, and use of proceeds.

+ 8 other (3 earnings 8-Ks · 2 10-Qs · 2 proxys · 1 ARS) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Contact Kessler Topaz Meltzer & Check, LLPgurufocus.com·11d agoImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Contact Kessler Topaz Meltzer & Check, LLPprnewswire.com·11d agoBell & Brown Wealth Advisors LLC Makes New $657,000 Investment in ImmunityBio, Inc. $IBRXdefenseworld.net·12d agoBank of America Corp DE Increases Position in ImmunityBio, Inc. $IBRXdefenseworld.net·12d agoImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairmanbusinesswire.com·22d ago

In themes

Explore the broader themes this ticker is being talked about under.

AI Precision Medicine

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALT$AURA$IOVA$NWBO$SLS$AMLX$ABCL
Voices on X · top 15 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport